

Beyond HRSA: 340B risks related to Medicare and Medicaid

Government Contract Services
July 2023



Building a better
working world

340B covered entities focus a lot of compliance efforts on parts of the program governed by the Health Services and Resources Administration (HRSA), but is enough attention being given to **non-HRSA compliance obligations**? These obligations include:

Medicaid risks

Beyond duplicate discount prevention, state Medicaid programs often impose challenging and cumbersome 340B-specific billing obligations on covered entities. Billing Medicaid incorrectly can cause you to receive Medicaid dollars you are not otherwise entitled to. Billing Medicaid correctly is difficult because each state can have different billing rules, and rules can even differ between retail and institutional settings. What's more, seemingly small errors on government programs can cause you big problems.

340B covered entities should consider the following when evaluating 340B drug billings to Medicaid payers:

- 1 What states are you billing and what are their rules for 340B drugs?
- 2 What systems and/or vendors are responsible for making sure that your Medicaid bills are built correctly?
- 3 Are you keeping up on your institutional and retail pharmacy risks related to Medicaid billing?
- 4 What steps are you taking to mitigate your risk (e.g., third-party audit)?
- 5 What operational and procedural challenges are you facing to comply with 340B Medicaid rules?

Medicare risks

Medicare's 340B rules are consistent from state to state but have recently been in flux, which may cause uncertainty about billing obligations and associated risks. Additionally, recent Medicare changes offer financial opportunities that covered entities might not be leveraging.

340B covered entities should consider the following when evaluating their 340B Medicare risk:

- 1 What processes are in place to establish that your Medicare charges are built correctly?
- 2 What efforts have you taken to recover underpayments from Medicare Part B and Medicare Advantage Plans?
- 3 Is access to 340B pricing a factor your covered entity generally considers when enrolling in Medicare reimbursement programs?

Key examples of non-HRSA risks

Claim modifiers are used by Medicare and Medicaid to identify 340B drugs

Billing the NDC actually dispensed is required by many state Medicaid agencies

Federal health care programs bring with them risks of false claims and overpayment liability

Qui tam actions could be brought against covered entities by their own employees

Hospital access to orphan drugs could depend on enrollment status with CMS, not HRSA

Government Contract Services

Ernst & Young LLP



Alexandra Mooney Bonelli
Principal
+1 212 773 4733
alexandra.mooney@ey.com



Garrett Pape
Senior Manager
+1 312 879 5791
garrett.pape@ey.com



Matt Newman
Manager
+1 202 327 5714
matthew.newman@ey.com

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

About EY Forensic & Integrity Services

Embedding integrity into an organization's strategic vision and day-to-day operations is critical when managing complex issues of fraud, regulatory compliance, investigations and business disputes. Our international team of more than 4,000 forensic and technology professionals helps leaders balance business objectives and risks, build data-centric ethics and compliance programs, and ultimately develop a culture of integrity. We consider your distinct circumstances and needs to assemble the right multidisciplinary and culturally aligned team for you and your legal advisors. We strive to bring you the benefits of our leading technology, deep subject-matter knowledge and broad global sector experience.

© 2023 Ernst & Young LLP. All Rights Reserved.

US SCORE no. 19908-231US

2305-4253251

ED None

This material has been prepared for general informational purposes only and is not intended to be relied upon as accounting, tax, legal or other professional advice. Please refer to your advisors for specific advice.

ey.com/forensics/governmentcontractservices